Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.39 |
| ▸ | CCNK | O75909 | 3/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 3/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23147937 | 1.00 | DAO (0.41) | DAOIDO1TDO2NUDT1CCNK | |
| SCHEMBL29721793 | 0.87 | NUDT1 (0.51) | NUDT1CCNKCDK12MAPTGSK3A | |
| SCHEMBL29722004 | 0.80 | IDO1 (0.49) | DAOIDO1TDO2NUDT1CCNK | |
| SCHEMBL3008612 | 0.80 | IDO1 (0.49) | DAOIDO1TDO2NUDT1CCNK | |
| SCHEMBL7976646 | 0.78 | DAO (0.45) | DAOIDO1TDO2NUDT1CCNK | |
| SCHEMBL23147945 | 0.77 | NUDT1 (0.51) | NUDT1 | |
| SCHEMBL23147745 | 0.76 | NUDT1 (0.44) | DAOIDO1TDO2NUDT1CCNK | |
| SCHEMBL20839678 | 0.76 | GRIN1 (0.46) | DAOIDO1TDO2NUDT1RHEB | |
| SCHEMBL22554070 | 0.76 | DAO (0.44) | DAOIDO1TDO2NUDT1CCNK | |
| SCHEMBL30731002 | 0.76 | DAO (0.44) | DAOIDO1TDO2NUDT1CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4034108-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746090-A | Azaindole carboxamide compounds for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | DAO 778/4885IDO1 16/4885TDO2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.